We are very delighted to work with Merck KGaA, Darmstadt, Germany, a precision medicine driven company. We have a shared vision of the critical role of liquid biopsy in revolutionizing personalized cancer treatments and clinical drug development.
HAYWARD, Calif. (PRWEB) January 07, 2020
Predicine, a molecular insights company headquartered in Hayward, California, with global footprints in China, today announced results from a collaborative biomarker study with Merck KGaA, Darmstadt, Germany, a leading science and technology company operating its biopharmaceuticals business in the U.S. and Canada as EMD Serono, will be jointly presented at the American Association for Cancer Research (AACR) - Advances in Liquid Biopsies Conference, taking place from January 13 to 16, 2020 in Miami, Florida. The study explores the potential clinical utility of Predicine’s proprietary liquid biopsy platforms for detection of genetic alterations using plasma-derived circulated tumor DNA (ctDNA) and cell-free RNA (cfRNA) in patients with advanced colorectal cancer (CRC).
Highlights of this study include:
- The clinical feasibility of simultaneous multiparametric profiling using a combined cfDNA and cfRNA liquid biopsy approach for molecular characterization in advanced CRC.
- cfRNA-derived variant detection confirms the variants originally detected in cfDNA test and validates the high specificity results for report interpretation.
- cfDNA-based detection of tumor mutation burden (TMB).
Data to be presented also support the role of clinical implementation of a combined cfDNA and cfRNA test that could provide holistic molecular insight for detecting cancer driver mutations, monitoring efficacy/disease burden, as well as identifying sub-clonal alterations that may be relevant to drug resistance and tumor heterogeneity.
“We are very delighted to work with Merck KGaA, Darmstadt, Germany, a precision medicine driven company. We have a shared vision of the critical role of liquid biopsy in revolutionizing personalized cancer treatments and clinical drug development,” said Dr. Shidong Jia, Founder and CEO at Predicine. “Predicine’s next-generation sequencing-based comprehensive non-invasive liquid biopsy platform adds value by enabling biomarker-driven patient selection & enrollment, longitudinal disease monitoring and exploring the new paradigm for both targeted and combination therapies.”
Predicine is a molecular insights company that is committed to advancing biomarker-driven precision medicine. Predicine has developed a breakthrough RNA- and DNA-based liquid biopsy technology for non-invasive cancer profiling, disease monitoring and assessing minimal residual disease. Through its CLIA and/or CAP facilities in the US and China, Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer therapy.